Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.
AmoyDx pan lung cancer PCR panel
Oncomine Dx Target Test
nonsmall‐cell lung cancer
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
revised:
18
03
2024
received:
11
11
2023
accepted:
26
03
2024
medline:
4
4
2024
pubmed:
4
4
2024
entrez:
4
4
2024
Statut:
ppublish
Résumé
Genetic mutation detection has become an important step in nonsmall-cell lung cancer (NSCLC) treatment because of the increasing number of drugs that target genomic rearrangements. A multiplex test that can detect multiple gene mutations prior to treatment is thus necessary. Currently, either next-generation sequencing (NGS)-based or polymerase chain reaction (PCR)-based tests are used. We evaluated the performance of the Oncomine Dx Target Test (ODxTT), an NGS-based multiplex biomarker panel test, and the AmoyDx Pan Lung Cancer PCR Panel (AmoyDx PLC panel), a real-time PCR-based multiplex biomarker panel test. Patients with histologically diagnosed NSCLC and a sufficient sample volume to simultaneously perform the AmoyDx PLC panel and ODxTT-M were included in the study. The success and detection rates of both tests were evaluated. Biopsies revealed 116 cases of malignancies, 100 of which were NSCLC. Of these, 59 met the inclusion criteria and were eligible for analysis. The success rates were 100% and 98% for AmoyDx PLC panel and ODxTT-M, respectively. Nine driver mutations were detected in 35.9% and 37.3% of AmoyDx PLC and ODxTT-M panels, respectively. EGFR mutations were detected in 14% and 12% of samples using the AmoyDx PLC panel and ODxTT-M, respectively. Of the 58 cases in which both NGS and AmoyDx PLC panels were successful, discordant results were observed in seven cases. These differences were mainly due to different sensitivities of the detection methods used and the gene variants targeted in each test. The AmoyDx PLC panel, a PCR-based multiplex diagnostic test, exhibits a high success rate. The frequency of the nine genes targeted for treatment detected by the AmoyDx PLC panel was comparable to the frequency of mutations detected by ODxTT-M. Clinicians should understand and use the AmoyDx PLC panel and ODxTT-M with respect to their respective performances and limitations.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e7162Subventions
Organisme : Riken Genesis Co., Ltd.
Informations de copyright
© 2024 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Herbst RS, Morgensztern D, Boshoff C. The biology and management of non‐small cell lung cancer. Nature. 2018;553(7689):446‐454.
Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998‐2006.
Yatabe Y, Sunami K, Goto K, et al. Multiplex gene‐panel testing for lung cancer patients. Pathol Int. 2020;70(12):921‐931.
Sakata S, Otsubo K, Yoshida H, et al. Real‐world data on NGS using the Oncomine DxTT for detecting genetic alterations in non‐small‐cell lung cancer: WJOG13019L. Cancer Sci. 2022;113(1):221‐228.
Murakami S, Yokose T, Nemoto D, et al. Suitability of Bronchoscopic biopsy tissue samples for next‐generation sequencing. Diagnostics (Basel). 2021;11(3):391.
Nemoto D, Yokose T, Katayama K, et al. Tissue surface area and tumor cell count affect the success rate of the Oncomine Dx Target Test in the analysis of biopsy tissue samples. Thorac Cancer. 2021;12(2):194‐200.
Murakami S, Yokose T, Shinada K, et al. Comparison of next‐generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations. Thorac Cancer. 2022;13(22):3217‐3224.
Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243‐1260.
Manabe S, Kasajima R, Murakami S, et al. Analysis of targeted somatic mutations in pleomorphic carcinoma of the lung using next‐generation sequencing technique. Thorac Cancer. 2020;11(8):2262‐2269.
Kunimasa K, Matsumoto S, Kawamura T, et al. Clinical application of the AMOY 9‐in‐1 panel to lung cancer patients. Lung Cancer. 2023;179:107190.
Yang G, Liu C, Hu J, et al. The lifted veil of uncommon EGFR mutation p.L747P in non‐small cell lung cancer: molecular feature and targeting sensitivity to tyrosine kinase inhibitors. Front Oncol. 2022;12:843299.
Vaclova T, Chakraborty A, Sherwood J, et al. Concomitant KRAS mutations attenuate sensitivity of non‐small cell lung cancer cells to KRAS G12C inhibition. Sci Rep. 2022;12(1):2699.
Teishikata T, Shiraishi K, Shinno Y, et al. An alert to possible false positives with a commercial assay for MET exon 14 skipping. J Thorac Oncol. 2021;16(12):2133‐2138.
Nakayama Y, Yamaguchi H, Einaga N, Esumi M. Pitfalls of DNA quantification using DNA‐binding fluorescent dyes and suggested solutions. PLoS One. 2016;11(3):e0150528.
Simbolo M, Gottardi M, Corbo V, et al. DNA qualification workflow for next generation sequencing of histopathological samples. PLoS One. 2013;8(6):e62692.
Sunami K, Ichikawa H, Kubo T, et al. Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: a hospital‐based study. Cancer Sci. 2019;110(4):1480‐1490.
Mizuno T, Fujiwara Y, Yamamoto N, et al. 01‐102 actionable gene aberration and the response of matched therapy among patients with non‐small‐cell lung carcinoma. J Thorac Oncol. 2019;14(10):S401.